AB0212 Clinical and sociodemographic characteristics associated with response to methotrexate (MTX) in a cohort of patients with rheumatoid arthritis (RA) naÏve to dmard

Background RA treatment involves starting early with a DMARD. MTX achieves good sustained response in 30–40% of patients (pts). When MTX response is insufficient add other DMARD by achieve RA remission. Different factors may affect the response to MTX Objectives To analyze the clinical and demographic characteristics related to response to MTX in RA pts DMARD-naive Methods We enrolled between 2011 and 2015, pts>18years RA diagnosed (ACR 1987 criteria), treated firs with MTX monotherapy (MTXm). A case-control study (MTXm persistence with CRP-DAS28 Results We included 222 pts (70 men and 152 women). The characteristics of cases (123) and controls (99) are shown in the table. The causes of MTXm suspension were remission (7), intolerance/toxicity (19) and inefficiency (79). MTX was discontinued in 40 (18.2%) pts, 28 (12.7%) of them by intolerance/toxicity. Of 123 (55.4%) responders, 71 (32.0%) were CRP-DAS28 Conclusions The initial treatment of RA with MTX is an effective and safe option, with a high drug survival. MTX response was not associated with antibody positivity (RF or ACPA), but it was significantly better in non-smokers patients and RF References Saevarsdottir S, et al. Arthritis Rheum 2011;63:26–36. V. K. Ranganath et al. Rheumatology 2013;52:1809–1817. Disclosure of Interest None declared